Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems

References

• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–15.
   PubMed Web of Science ®Google Scholar
• Mardigan MT, Martinko JM, Parker J. Brock biology of microorganisms, 9th ed. New York: Prentice-Hill International Inc.; 2000.
   Google Scholar
• Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22:283–97.
   PubMed Web of Science ®Google Scholar
• Peleteiro B, Bastos A, Ferro A, et al. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014;59:1698–709.
   PubMed Web of Science ®Google Scholar
• Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000;54:615–40.
   PubMed Web of Science ®Google Scholar
• Velazquez M, Feirtag JM. Helicobacter pylori: characteristics, pathogenicity, detection methods and mode of transmission implicating foods and water. Int J Food Microbiol 1999;53:95–104.
   PubMed Web of Science ®Google Scholar
• Lambert JR. Pharmacology of the gastric mucosa: a rational approach to Helicobacterpolytherapy. Gastroenterology 1996;111:521–3.
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Leying H, Klemm K, et al. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991;10:92–3.
   PubMed Web of Science ®Google Scholar
• Uunge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996;31:74–81.
   PubMed Web of Science ®Google Scholar
• Graham DY, De Boer WA, Tytgat NNJ. Choosing the bestanti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072–6.
   PubMed Web of Science ®Google Scholar
• Nijevitch AA, Shcherbakov PL, Sataev VU, et al. Helicobacter pylorieradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone. Aliment Pharmacol Ther 2005;22:881–7.
   PubMed Web of Science ®Google Scholar
• Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. GUT 2004;53:1374–84.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. GUT 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos GK, Kostopoulos P, Margantinis G, et al. Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pyloriinfection. J Clin Gastroenterol 2003;36:325–8.
   PubMed Web of Science ®Google Scholar
• Tindberg Y, Casswall TH, Blennow M, et al. Helicobacter pylorieradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. Aliment Pharmacol Ther 2004;20:295–302.
   PubMed Web of Science ®Google Scholar
• Iacopini F, Crispino P, Paoluzi OA, et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylorieradication. Dig Liver Dis 2005;37:571–6.
   PubMedGoogle Scholar
• Caselli M, Parente F, Palli D, et al. Cervia Working Group Report: guidelines on the diagnosis and treatment of Helicobacter pylori infection. Dig Liver Dis 2001;33:75–80.
   PubMedGoogle Scholar
• Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167–80.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339–43.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35:711–15.
   PubMedGoogle Scholar
• Marzio L, Coraggio D, Capodicasa S, et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006;11:237–42.
   PubMed Web of Science ®Google Scholar
• Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45–9.
   PubMed Web of Science ®Google Scholar
• Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple Moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16:527–32.
   PubMed Web of Science ®Google Scholar
• Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;21:1241–7.
   PubMed Web of Science ®Google Scholar
• Perri F, Festa V, Clemente R, et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori-infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311–16.
   PubMed Web of Science ®Google Scholar
• Toracchio S, Capodicasa S, Soraja DB, et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005;37:33–8.
   PubMedGoogle Scholar
• Marshall BJ. The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology. Am J Gastroenterol 1991;86:16–25.
   PubMed Web of Science ®Google Scholar
• Adachi K, Ishihara S, Hashimoto T, et al. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther 2000;14:919–22.
   PubMed Web of Science ®Google Scholar
• Francesco VD, Ierardi E, Hassan C, et al. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012;3:68–73.
   PubMedGoogle Scholar
• Bhaskar KR, Gong DH, Bansil R, et al. Profound increase in viscosity and aggregation of pig gastric mucin at low pH. Am J Physiol 1991;261:G827–32.
   PubMed Web of Science ®Google Scholar
• Cederbrant G, Kahlmeter G, Schalén C, et al. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994;34:1025–9.
   PubMed Web of Science ®Google Scholar
• Kusters JG, Gerrits MM,Van Strijp JA, et al. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun 1997; 65:3672–9.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. GUT 2007;56:772–81.
   PubMed Web of Science ®Google Scholar
• Jafri NS, Hornung CA, Howden CW, et al. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923–31.
   PubMed Web of Science ®Google Scholar
• Jung YS, Lee SH, Park CS, et al. Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol 2014;63:82–9.
   PubMedGoogle Scholar
• Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol 2010;5:639–48.
   PubMed Web of Science ®Google Scholar
• Demir M, Göktürk S, Oztürk NA, et al. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion 2010;82:47–53.
   PubMed Web of Science ®Google Scholar
• Borody TJ. Method for treatment of gastro intestinal disorders. United States Patent 5196205, March 23, 1993.
   Google Scholar
• Neeman I, Tabak M, Armon R. Therapeutic application of a thyme extract and in vitro methods for inhibiting the growth and urease activity of Helicobacter Pylori. United States Patent 5472695, May 12, 1995.
   Google Scholar
• Neeman I, Tabak M, Armon R. Method for inhibiting growth of Helicobacter pylori. United States Patent 5,560,912, 12 May 1995; 27 June 1994.
   Google Scholar
• Shell JW. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms. United States Patent 5,582,837, 10 December 1996.
   Google Scholar
• McLoughlin R, Racz I, Buckley M, et al. Therapy of Helicobacter pylori. Helicobacter 2004;9:42–8.
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv 2006;3:217–33.
   PubMed Web of Science ®Google Scholar
• Tuleu C, Andrieux C, Boy P, et al. Gastrointestinal transit of pelletsin rats: effect of size and density. Int J Pharm 1999;180:123–31.
   PubMed Web of Science ®Google Scholar
• Riner JL, Byford RL, Stratton LG, et al. Influence of density and location on degradation of sustained-release boluses given to cattle. Am J Vet Res 1982;43:2028–30.
   PubMed Web of Science ®Google Scholar
• Cardinal JR. Controlled drug delivery: veterinary applications. J Control Release 1985;2:393–403.
   Google Scholar
• Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;63:235–59.
   PubMed Web of Science ®Google Scholar
• Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems: a review. Asian J Pharm Clin Res 2010;3:2–10.
   Google Scholar
• Hao S, Wang Y, Wang B. Sinking-magnetic microparticles prepared by the electrospray method for enhanced gastric antimicrobial delivery. Mol Pharm 2014;11:1640–50.
   PubMed Web of Science ®Google Scholar
• Mazer N, Abisch E, Gfeller JC, et al. Intragastric behavior and absorption kinetics of a normal and “under fasted and fed conditions” modified-release capsule of isradipine under fasted and fed. J Pharm Sci 1988;77:647–57.
   PubMed Web of Science ®Google Scholar
• Arora S, Ali J, Ahuja A, et al. Floating drug delivery systems: a review. AAPS PharmSciTech 2005;6: E372–90.
   PubMed Web of Science ®Google Scholar
• Saito N, Konishi K, Sato F, et al. Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability. J Infect 2003;46:49–55.
   PubMed Web of Science ®Google Scholar
• Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology 1985;89:392–7.
   PubMed Web of Science ®Google Scholar
• Whitehead L, Fell JT, Collett JH, et al. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release 1998;55:3–12.
   PubMed Web of Science ®Google Scholar
• Steingoetter A, Kunz P, Weishaupt D, et al. Analysis of the meal-dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;18:713–20.
   PubMed Web of Science ®Google Scholar
• Tripathi G, Singh S. Formulation and in vitro evaluation of pH sensitive oil entrapped polymeric blended gellan gum buoyant beads of clarithromycin. DARU 2010;18:247–53.
   PubMed Web of Science ®Google Scholar
• Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules. United States Patent 4,126,672, 21 November 1978.
   Google Scholar
• Sheth PR, Tossounian JL. Novel sustained release tablet formulation. United States Patent 4,167,558, 11 September 1979.
   Google Scholar
• Kumar V, Ahmad S, Singh RB. A gastroretentive dosage system and process of preparation thereof. WO 2013054285 A1, 18 April 2013.
   Google Scholar
• Xu WL, Tu XD, Lu XD. Development of Gentamicin sulfate sustained release tablet remaining-floating in stomach. Acta Pharm Sin 1991;26:541–5.
   Google Scholar
• Ali J, Hasan S, Ali M. Formulation and development of gastroretentive drug delivery system for ofloxacin. Methods Find Exp Clin Pharmacol 2006;28:433–9.
   PubMedGoogle Scholar
• Alessandra R, Chiara C, Gaia C, et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Dev Ind Pharm 2016;42:332–9.
   PubMed Web of Science ®Google Scholar
• Mouzam MI, Dehghan MH, Asif S, et al. Preparation of a novel floating ring capsule-type dosage form for stomach specific delivery. Saudi Pharm J 2011;19:85–93.
   PubMed Web of Science ®Google Scholar
• Nama M, Gonugunta CSR, Veerareddy PR. Formulation and evaluation of gastroretentive dosage forms of clarithromycin. AAPS PharmSciTech 2008;9:231–7.
   PubMed Web of Science ®Google Scholar
• Ranade AN, Wankhede SS, Ranpise NS, et al. Development of bilayer floating tablet of amoxicillin and Aloe vera gel powder for treatment of gastric ulcers. AAPS PharmSciTech 2012;13:1518–23.
   PubMed Web of Science ®Google Scholar
• Patel SS, Ray S, Thakur RS. Formualtion and evaluation of floating drug delivery system containing clarithromycin for Helicobacter pylori. Acta Pol Pharm 2006;63:53–61.
   PubMedGoogle Scholar
• Prabaharan M, Mano JF. Stimuli–responsive hydrogels based on polysaccharides incorporated with thermo-responsive polymers as novel biomaterials. Macromol Biosci 2006;6:991–1008.
   PubMed Web of Science ®Google Scholar
• Ramesh CR, Gaylen MZ, Byeongmoon J. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. United States Patent: 6,201,072, 15 September 1999.
   Google Scholar
• Ramesh CR, Gaylen MZ, Byeongmoon J. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. United States Patent: 6,117,949, 12 September 2000.
   Google Scholar
• Ramesh CR, Gaylen MZ. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. United States Patent: 6004573, 21 December 1999.
   Google Scholar
• Rajinikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int J Pharm 2007;335:114–22.
   PubMed Web of Science ®Google Scholar
• Rajinikanth PS, Mishra B. Floating in situ gelling system for stomach site-specific delivery of Clarithromycin to eradicate H. pylori. J Control Release 2008;125:33–41.
   PubMed Web of Science ®Google Scholar
• Washington N. Investigation into the barrier action of an alginate gastric reflux suppressant, liquid gaviscon. Drug Invest 1990;2:23–30.
   Google Scholar
• Foldager J, Toftkjor H, Kjornos K. Antacid composition. United States Patent 5068109, 26 November 1991.
   Google Scholar
• Peter WD, John GL. Method of treatment of Heliobacter pylori infections with Triclosan. United States Patent 5286492, 15 Febraury 1994.
   Google Scholar
• Fabregas JL, Claramunt J, Cucala J, et al. In vitro testing of an antacid formulation with prolonged gastric residence time (Almagate Flot-Coat). Drug Dev Ind Pharm 1994;20:1199–212.
   Web of Science ®Google Scholar
• Yokoyama H, Hirata A, Hamamoto H, et al. Liquid matrix undergoing phase transfer in vivo and liquid oral preparations. EP 1488812 A1, 22 December 2004.
   Google Scholar
• Nancy Abdel Hamid AY, Abeer AK, Magda Abd Elsamea EL-M, et al. Development of gastroretentive metronidazole floating raft system for targeting Helicobacter pylori. Int J Pharm 2015;486:297–305.
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Kulkarni AR, Rudzinski WE, et al. Microspheres as floating drug-delivery systems to increase gastric retention of drugs. Drug Metab Rev 2001;33:149–60.
   PubMed Web of Science ®Google Scholar
• Zhai H, Jones DS, McCoy CP, et al. Gastroretentive extended-release floating granules prepared using a novel fluidized hot melt granulation (FHMG) technique. Mol Pharm 2014;11:3471–83.
   PubMed Web of Science ®Google Scholar
• Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv 2003;10:151–60.
   PubMed Web of Science ®Google Scholar
• Rajinikanth PS, Mishra B. Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm 2007;57:413–27.
   PubMedGoogle Scholar
• Rajinikanth PS, Mishra B. Stomach-site specific drug delivery system of Clarithromycin for eradication of Helicobacter pylori. Chem Pharm Bull 2009;57:1068–75. (Tokyo).
   PubMed Web of Science ®Google Scholar
• Badhan AC, Mashru RC, Shah PP. Development and evaluation of sustained release gastroretentive minimatrices for effective treatment of H. pylori infection. AAPS PharmSciTech 2009;10:2459–67.
   Web of Science ®Google Scholar
• Javadzadeh Y, Hamedeyazdan S, Adibkia K, et al. Evaluation of drug release kinetics and physico-chemical characteristics of metronidazole floating beads based on calcium silicate and gas-forming agents. Pharm Dev Technol 2010;15:329–38.
   PubMed Web of Science ®Google Scholar
• Hao S, Wang Y, Wang B, et al. A novel gastroretentive porous microparticle for anti-Helicobacter pylori therapy: preparation, in vitro and in vivo evaluation. Int J Pharm 2014;463:10–21.
   PubMed Web of Science ®Google Scholar
• Choudhary S, Jain A, Amin MC, et al. Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer. Colloids Surf B Biointerfaces 2016;141:268–77.
   PubMed Web of Science ®Google Scholar
• Adebisi AO, Conway BR. Preparation and characterisation of gastroretentive alginate beads for targeting H. pylori. J Microencapsul 2014;31:58–67.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Kulkarni GT, Pawar VK, et al. Optimization studies on gastroretentive floating system using response surface methodology. AAPS PharmSciTech 2012;13:85–93.
   PubMed Web of Science ®Google Scholar
• El-Zahaby SA, Kassema AA, El-Kamel AH. Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori. Saudi Pharm J 2014;22:570–9.
   PubMed Web of Science ®Google Scholar
• Nagahara N, Akiyama Y, Nakao M, et al. Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother 1998;42:2492–4.
   PubMed Web of Science ®Google Scholar
• Wang J, Tauchi Y, Deguchi Y, et al. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of H. pylori. Drug Deliv 2000;7:237–43.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Singla AK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004;274:1–33.
   PubMed Web of Science ®Google Scholar
• Hejazi R, Amiji M. Stomach-specific anti-H. Pylori therapy. I: preparation and characterization of tetracyline-loaded chitosan microspheres. Int J Pharm 2002;235:87–94.
   PubMed Web of Science ®Google Scholar
• Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy. II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm Dev Technol 2003;8:253–62.
   PubMed Web of Science ®Google Scholar
• Säkkinen M, Marvola J, Kanerva H, et al. Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach. Eur J Pharm Biopharm 2004;57:133–43.
   PubMed Web of Science ®Google Scholar
• Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy; Part III: effect of chitosan microspheres crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils. Int J Pharm 2004;272:99–108.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lu W, Qian L, et al. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release 2005;102:135–44.
   PubMed Web of Science ®Google Scholar
• Higo S, Takeuchi H, Yamamoto H, et al. Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of Helicobacter pylori. Chem Pharm Bull 2008;56:1412–16. (Tokyo).
   PubMed Web of Science ®Google Scholar
• Umamaheswari RB, Jain S, Tripathi PK, et al. Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori. Drug Deliv 2002;9:223–31.
   PubMed Web of Science ®Google Scholar
• Zheng J, Liu C, Bao D, et al. Preparation and evaluation of floating-bioadhesive microparticles containing Clarithromycin for the eradication of Helicobacter pylori. J Appl Polym Sci 2006;102:2226–32.
   Web of Science ®Google Scholar
• Adebisi AO, Laity PR, Conway BR. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori. J Pharm Pharmacol 2015;67:511–24.
   PubMed Web of Science ®Google Scholar
• Nilima AT, Paraag SG. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication. Drug Deliv 2016;23:405–19.
   PubMed Web of Science ®Google Scholar
• Diós P, Nagy S, Pál S, et al. Preformulation studies and optimization of sodium alginate based floating drug delivery system for eradication of Helicobacter pylori. Eur J Pharm Biopharm 2015;96:196–206.
   PubMed Web of Science ®Google Scholar
• Rajput P, Singh D, Pathak K. Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. Int J Pharm 2014;461:310–21.
   PubMed Web of Science ®Google Scholar
• Viness P, Yahya C, Caragh M, et al. A gastroretentivepharmaceutical dosage form. WO2009153632A1; Publication date 23 December 2009.
   Google Scholar
• Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998;15:243–84.
   PubMed Web of Science ®Google Scholar
• Mohammad H. Gastroretentive Drug Delivery System Comprising an Extruded Hydratable Polymer. United States Patent, 8,586,083 B2 19 November 2013.
   Google Scholar
• Fix JA, Cargill R, Engle K. Controlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteers. Pharm Res 1993;10:1087–9.
   PubMed Web of Science ®Google Scholar
• Cargill R, Caldwell LJ, Engle K, et al. Controlled gastric emptying. 1. Effects of physical properties on gastric residence times of non-disintegrating geometric shapes in beagle dogs. Pharm Res 1988;5:533–6.
   PubMed Web of Science ®Google Scholar
• Mohammad H. Gastroretentive drug delivery system comprising an extruded hydratable polymer. UK Patent 1 601 923 (Beecham Group Ltd), 1977.
   Google Scholar
• El-Zahaby SA, Kassem AA, El-Kamel AH. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate. Int J Pharm 2014;464:10–18.
   PubMed Web of Science ®Google Scholar
• Davis SS, Illum L, Hinchcliffe M. Gastrointestinal transit of dosage forms in the Pig. J Pharm Pharmacol 2001;53:33–9.
   PubMed Web of Science ®Google Scholar
• Atyabi F, Sharma HL, Mohammad HAH, et al. Controlled drug release from coated floating ion exchange resin beads. J Control Release 1996;42:25–8.
   Web of Science ®Google Scholar
• Atyabi F, Sharma HL, Mohammad HAH, et al. In vivo evaluation of a novelgastric retentive formulation based on ion exchange resins. J Control Release 1996;42:105–13.
   Web of Science ®Google Scholar
• Cuña M, Alonso MJ, Torres D. Preparation and in vivo evaluation of mucoadhesive micro particles containing amoxycillin–resin complexes for drug delivery to the gastric mucosa. Eur J Pharm Biopharm 2001;51:199–205.
   PubMed Web of Science ®Google Scholar
• Chen J, Blevins WE, Park H, et al. Gastric retention properties of Superporous hydrogel composites. J Control Release 2000;64:39–51.
   PubMed Web of Science ®Google Scholar
• Bardonnet PL, Faivre V, Pugh WJ, et al. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release 2006;111:1–18.
   PubMed Web of Science ®Google Scholar
• Rocca J, Shah K, Omidian H. Superporous hydrogels containing solid and semi-solid carriers. Gattefossé Technical Bull 2004;97:73–84.
   Google Scholar
• Horowitz M, Dent J, Fraser R, et al. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994;39:7–13.
   PubMed Web of Science ®Google Scholar
• De la Torre PM, Torrado G, Torrado S. Poly (acrylic acid) chitosan inter-polymer complexes for stomach controlled antibiotic delivery. J Biomed Mater Res B Appl Biomater 2005;72:191–7.
   PubMed Web of Science ®Google Scholar
• Park J, Kim D. Release behavior of amoxicillin from glycol chitosan Superporous hydrogels. J Biomater Sci Polym Ed 2009;20:853–62.
   PubMed Web of Science ®Google Scholar
• Jain SK, Jangdey MS. Lectin conjugated gastroretentive mutiparticulate delivery system of Clarithromycin for the effective treatment of Helicobacter pylori. Mol Pharm 2009;6:295–304.
   PubMed Web of Science ®Google Scholar
• Singh A, Jain R. Targeted vesicular constructs for cyto protection and treatment of H. pylori. United States Patent 6306838 B1, 23 October 2001.
   Google Scholar
• Adebisi AO, Conway BR. Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. Int JPharm 2014;470:28–40.
   PubMed Web of Science ®Google Scholar
• Lin YH, Tsai SC, Lai CH, et al. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 2013;4:4466–79.
   Web of Science ®Google Scholar
• Chang CH, Huang WY, Lai CH, et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta Biomater 2011;7:593–603.
   PubMed Web of Science ®Google Scholar
• Lin YH, Chiou SF, Lai CH, et al. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication. Process Bio Chem 2012;47:1469–78.
   Web of Science ®Google Scholar
• Gonçalves IC, Magalhães A, Fernandes M, et al. Bacterial-binding chitosan microspheres for gastric infection treatment and prevention. Acta Biomater 2013;9:9370–8.
   PubMed Web of Science ®Google Scholar
• Tachaprutinun A, Pan-In P, Samutprasert P, et al. Acrylate-tethering drugcarrier: covalently linking carrier to biological surface and application in the treatment of Helicobacter pylori infection. Biomacromolecules 2014;15:4239–48.
   PubMed Web of Science ®Google Scholar
• Zhang BL, Jing ZW, Jia YY, et al. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori. Biomaterials 2016;84:276–85.
   PubMed Web of Science ®Google Scholar